Deutsch English Français

Contact

EP3757126

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP3757126

EP3757126 - METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS [Right-click to bookmark this link]
Status	Examination is in progress Status updated on 27.11.2020 Database last updated on 15.06.2024
Most recent event Tooltip	28.10.2023	New entry: Renewal fee paid
Applicant(s)	For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH
	[2021/01]
Inventor(s)	01 / MPOFU, Shepard Novartis Pharma AG Postfach 4002 Basel / CH
	02 / RICHARDS, Hanno Novartis Pharma AG Postfach 4002 Basel / CH
	03 / THANGAVELU, Karthinathan Novartis Pharma AG Postfach 4002 Basel / CH
	04 / MACHACEK, Matthias Novartis Pharma AG Postfach 4002 Basel / CH
	[2021/01]
Representative(s)	Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[N/P]
Former [2021/01]	Fredh, Fredrik Novartis Pharma AG Patent Department Postfach 4002 Basel / CH
Application number, filing date	20187001.1	04.11.2011
	[2021/01]
Priority number, date	US201041053310P	05.11.2010 Original published format: US 41053310 P
	[2021/01]
Previously filed application, date	EP20190162707	04.11.2011
	[2021/01]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP3757126
	Date:	30.12.2020
	Language:	EN
	[2020/53]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	09.11.2020
Classification	IPC:	C07K16/24, A61K39/395, A61K31/519	[2021/01]
	CPC:	A61K39/3955 (EP,IL,KR,US); A61K31/519 (EP,IL,KR,US); A61K39/39591 (EP,IL); A61K45/06 (IL,KR,US); A61P17/06 (EP,IL); A61P19/02 (EP,IL); (+) A61P29/00 (EP,IL); A61P37/00 (EP,IL); A61P37/02 (EP,IL); A61P37/06 (EP,IL); A61P43/00 (EP,IL); C07K16/244 (EP,IL,KR,US); A61K2039/505 (EP,IL,KR,US); A61K2039/545 (EP,IL,KR,US); A61K2039/55 (EP,IL,KR,US); A61K2300/00 (IL,KR); C07K2317/21 (EP,IL,KR,US); C07K2317/34 (EP,IL,KR,US); C07K2317/76 (EP,IL,KR,US); C07K2317/90 (EP,IL,US) (-)
	C-Set:	A61K39/3955, A61K2300/00 (EP,US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/08]
Former [2021/01]	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Extension states	BA	21.07.2020
	ME	21.07.2020
Title	German:	VERFAHREN ZUR BEHANDLUNG VON PSORIASUS-ARTHRITIS MIT IL-17 ANTAGONISTEN	[2021/01]
	English:	METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS	[2021/01]
	French:	MÉTHODES DE TRAITEMENT DE LA POLYARTHRITE PSORIASIQUE AU MOYEN D'ANTAGONISTES D'IL-17	[2021/01]
Examination procedure	21.07.2020	Examination requested [2020/53]
	09.11.2020	Date on which the examining division has become responsible
	23.11.2020	Despatch of a communication from the examining division (Time limit: M04)
	18.12.2020	Reply to a communication from the examining division
	17.02.2021	Despatch of a communication from the examining division (Time limit: M06)
	18.06.2021	Reply to a communication from the examining division
	14.01.2022	Despatch of a communication from the examining division (Time limit: M04)
	24.05.2022	Reply to a communication from the examining division
	28.11.2022	Despatch of a communication from the examining division (Time limit: M06)
	30.06.2023	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	11.09.2023	Reply to a communication from the examining division
Parent application(s) Tooltip	EP11778903.2 / EP2635303
	EP16163440.7 / EP3111954
	EP19162707.4 / EP3542820
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	11.09.2023	Request for further processing filed
	11.09.2023	Full payment received (date of receipt of payment) Request granted
	19.09.2023	Decision despatched
Fees paid	Renewal fee
	23.11.2020	Renewal fee patent year 03
	23.11.2020	Renewal fee patent year 04
	23.11.2020	Renewal fee patent year 05
	23.11.2020	Renewal fee patent year 06
	23.11.2020	Renewal fee patent year 07
	23.11.2020	Renewal fee patent year 08
	23.11.2020	Renewal fee patent year 09
	13.11.2020	Renewal fee patent year 10
	26.10.2021	Renewal fee patent year 11
	26.10.2022	Renewal fee patent year 12
	27.10.2023	Renewal fee patent year 13
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[Y]WO2006013107 (NOVARTIS AG [CH], et al) [Y] 1-8 * page 42, column 43 * * sequences 7-10 *;
		[Y] - MARK GENOVESE ET AL, "Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment: Results of a phase IIb study", ARTHRITIS & RHEUMATISM; ABSTRACTS OF THE AMERICAN COLLEGE OF RHEUMATOLOGY & ASSOCIATION OF RHEUMATOLOGY HEALTH PROFESSIONALS, ANNUAL SCIENTIFIC MEETING, JOHN WILEY & SONS, INC, US; ATLANTA, GEORGIA, USA, vol. 62, no. Suppl. 10, doi:10.1002/ART.30166, ISSN 0004-3591, (20101001), (20101228), XP008147986 [Y] 1-8 * the whole document * DOI: http://dx.doi.org/10.1002/art.30166
		[Y] - ERIK LUBBERTS, "Th17 cytokines and arthritis", SEMINARS IN IMMUNOPATHOLOGY, SPRINGER, BERLIN, DE, (20100204), vol. 32, no. 1, ISSN 1863-2300, pages 43 - 53, XP019800827 [Y] 1-8 * the whole document *
		[Y] - Anonymous, "History of Changes for Study: NCT00809614- Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis", ClinicalTrials.gov Archive, (20100429), pages 1 - 4, URL: https://clinicaltrials.gov/ct2/history/NCT00809614?A=5&B=5&C=merged#StudyPageTop, (20200123), XP055661176 [Y] 1-8 * the whole document *
		[Y] - NOVARTIS, "View of NCT00809159 on 2010_06_22", INTERNET CITATION, (20100622), URL: https://clinicaltrials.gov/archive/NCT00809159/2010_06_22, (20160907), XP002761819 [Y] 1-8 * the whole document *
		[YP] - MCINNES I ET AL, "Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial", INTERNET CITATION, ISSN 1529-0131, (20111104), URL: http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=781&id=95525, (20160914), XP002761820 [YP] 1-8 * the whole document *
		[YP] - BARALIAKOS XENOFON ET AL, "Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging", ARTHRITIS & RHEUMATISM; 75TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY/46TH ANNUAL SCIENTIFIC MEETIN; CHICAGO, IL, USA; NOVEMBER 04 -09, 2011, WILEY INTERSCIENCE, US, (20111101), vol. 63, no. 10, Suppl. S, ISSN 0004-3591, page S972, XP009170121 [YP] 1-8 * the whole document *
		[YP] - DOMINIQUE BAETEN ET AL, "The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis", ARTHRITIS & RHEUMATISM, (20101130), vol. 62, no. 12, pages 3840 - 3841, XP055660219 [YP] 1-8 * the whole document *
		[YP] - Stacey Ness, "Surveying the Pipeline of Biologics to Treat Inflammatory Conditions", (20110912), URL: https://www.pharmacytimes.com/publications/issue/2011/August2011/Surveying-the-Pipeline-of-Biologics-to-Treat-Inflammatory-Conditions-, (20200121), XP055660252 [YP] 1-8 * the whole document *
		[AP] - Anonymous, "History of Changes for Study: NCT01358175 Efficacy at 16 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients W Ankylosing Spondylitis (AS)", None (earliest Version on record) 2 October 20 Reported Adverse Events, Study Status, Outcome Measures and Baseline Characteristics Study NCT01358175 Submitted Date, (20111020), URL: https://clinicaltrials.gov/ct2/history/NCT01358175?V_2, (20201030), XP055745693 [AP] 1-8 * the whole document *
		[T] - DOMINIQUE BAETEN ET AL, "Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis", NEW ENGLAND JOURNAL OF MEDICINE, (20151224), vol. 373, no. 26, doi:10.1056/NEJMoa1505066, pages 2534 - 2548, XP055661305 DOI: http://dx.doi.org/10.1056/NEJMoa1505066
		[T] - JOHN COLLETT ED - AULTON M E (ED) 2, "DOSAGE REGIMENS", PHARMACEUTICS. THE SCIENCE OF DOSAGE FORM DESIGN ED. 2, CHURCHILL LIVIGSTONE, (20010101), no. 2nd Ed, ISBN 978-0-443-05517-1, pages 275 - 288, XP003030862

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p